Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor

Cell Cycle

Volumn 7, Issue 7, 2008, Pages 837-841

  Roeb, Wendy ^a   Boyer, Antonia ^a   Cavenee, Webster K ^a,b   Arden, Karen C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Alveolar; ARMS; EGR1; FKHR; p57kip2; PAX3 FOXO1; Rhabdomyosarcoma; Translocation; Unstable

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELDANAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

CANCER CELL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; DNA BINDING; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; MUSCLE CELL; MUSCLE TUMOR; NEOPLASM; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; RHABDOMYOSARCOMA; UBIQUITINATION;

EID: 42449117582     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.7.5652     Document Type: Review

References (31)

1. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006; 24:3844-51.
2. Weiss SW. Soft tissue tumors. St. Louis: Mosby, 2001.
3. Douglass EC, Shapiro DN, Valentine M, Rowe ST, Carroll AJ, Raney RB, Ragab AH, Abella SM, Parham DM. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993; 21:83-7.
4. Neville HL, Andrassy RJ, Lobe TE, Bagwell CE, Anderson JR, Womer RB, Crist WM, Wiener ES. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 2000; 35:317-21.
5. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 1999; 19:594-601.
6. Auerbach R. Analysis of the developmental effects of a lethal mutation in the house mouse. Journal of Experimental Zoology 1954; 127:305-29.
7. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. Embo J 1993; 12:2361-7.
8. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005; 24:1860-72.
9. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999; 96:13264-9.
10. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007.
11. Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA 2001; 98:1589-94.
12. Reynaud EG, Leibovitch MP, Tintignac LA, Pelpel K, Guillier M, Leibovitch SA. Stabilization of MyoD by direct binding to p57(Kip2). J Biol Chem 2000; 275:18767-76.
13. Reynaud EG, Pelpel K, Guillier M, Leibovitch MP, Leibovitch SA. p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. Mol Cell Biol 1999; 19:7621-9.
14. Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Huttinger Kirchhof N, Oswald C, Friedl P, Gattenlohner S, Burek C, Rosenwald A, Stiewe T. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006; 10:281-93.
15. Roeb W, Boyer A, Cavenee WK, Arden KC. PAX3-FOXO1 controls expression of p57Kip2 cell cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA 2007; 104:18085-90.
16. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992; 52:2243-7.
17. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995; 95:1606-11.
18. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000; 35:96-103.
19. Li FP, Fraumeni JF, Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43:1365-73.
20. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9:650-62.
21. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997; 387:151-8.
22. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 1989; 86:7480-4.
23. Tremblay P, Gruss P. Pax: genes for mice and men. Pharmacol Ther 1994; 61:205-26.
24. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92:1564-72.
25. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87:7071-5.
26. Jakob C, Egerer K, Liebisch P, Turkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J, Kleeberg L, Feist E, Burmester GR, Kloetzel PM, Sezer O. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007; 109:2100-5.
27. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4:290-6.
28. Kanagasabaphy P, Morgan GJ, Davies FE. Proteasome inhibition and multiple myeloma. Curr Opin Investig Drugs 2007; 8:447-51.
29. Demarchi F, Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist Updat 2005; 8:359-68.
30. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 2007; 43:1125-33.
31. Mercado GE, Barr FG. Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med 2007; 7:47-61.